Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Saliva (Spit) Virus Carrier Discovered By Sharon Kleyne & Taught To World On Kleyne Talk Radio


Sharon Kleyne, Founder of Bio Logic Aqua® Research

Sharon Kleyne, Founder of Bio Logic Aqua® Research

Air Date: 9 November 2020

Guest: Dr. Jill Maron is a Professor of Pediatrics and Vice Chair of Pediatric Research at Tufts Children’s Hospital, Boston, MA. Maron also serves as Executive Director of the Mother Infant Research Institute at Tufts Medical Center, a multi-disciplinary research enterprise conducting basic, translational and clinical science to advance maternal and newborn care.

https://www.voiceamerica.com/episode/126816/encore-the-power-of-neonatal-saliva

*

Sharon Kleyne, founder of Bio Logic Aqua® Research Water Life Science®, is a world leader in recognizing that the COVID-19 pandemic sheds a bright light on diagnostics. Scientists, researchers and physicians are scrambling like never before to decode and diagnose the virus in its rapidly-changing varieties and an unlikely path, neonatal saliva diagnostics, has emerged as an exciting, effective virus-busting tool.

Kleyne, leading the way in waking up the world to the significance of saliva (spit), welcomes Dr. Jill Maron, Executive Director of the Mother Infant Research Institute at Tufts Medical Center, a multi-disciplinary research enterprise conducting basic, translational and clinical science to advance maternal and newborn care where she cares for and studies premature and sick babies.

Maron tells Kleyne, host of the internationally syndicated The Power of Water® & Your Health sponsored by FDA approved Nature’s Tears® EyeMist®, natural pH balanced water technology for acid mantle immunity strength and protection, on VoiceAmerica World Talk Radio & Apple iTunes, “I fell in love with caring for babies,” says Maron. “One of the things I struggled with as a baby doctor was communicating with my patients because they can’t tell us how they’re feeling, telling us what hurts. It drove me into research to discover how I could give these babies a voice and help guide my path. Inspired me to focus over the last fifteen years on saliva, or spit, to discover platforms for diagnosis.

Our goal when we go into the neonatal intensive care units,” Maron continues, “is to look at these babies as individuals and personalize the care we give them.”

Spit has also been a research focus for Kleyne, who educates international audiences about the way spit carries Coronavirus. Kleyne urges Maron’s input and Maron references two ongoing research studies, NIH sponsored trials aimed at integrating a salivary infectious screening platform (Salivary Profiling in Infants Treated for Suspected Sepsis-SPITSS) and an oral feeding readiness platform (Neonatal Oral-feeding Readiness in Salivary High-throughput diagnostics- NOuRISH).

The premature babies Maron cares cannot produce much saliva, or spit. “In my patients, we get literally one drop of saliva,” Maron tells Kleyne, “and from there we’re able to interrogate that saliva for a broad range of developmental signals, inflammatory signals; it’s also a rich source of microbes. We can detect harmful organisms that could lead to infection. Saliva is providing us a window into the body, filtering blood….how the saliva changes week by week by week in these prematurely born babies. One of the powers of Saliva for me is that I can monitor how they’re developing and growing. I don’t have to stick them for blood.”

Kleyne speculates that studying saliva will help us better understand nutrition and addiction. Maron agrees. “How do we understand babies who struggle to eat? How do we better take care of them as their speech emerges? In partnership with Dr. Emily Zimmerman at Northeastern University, we’ve been able to follow babies looking at salivary biomarkers that we believe are shared between the ability to eat and ultimately the ability for our speech to emerge.” Maron stresses early recognition for early intervention.

Kleyne suspects that babies can be addicted to food and Maron believes that preferences for taste and smell can be indeed be passed on from parent to child. The Hypothalamus in the brain houses food sensors and drug receptors. Maron comments on babies born to mothers addicted to drugs. “As we wean them off of drugs,” says Maron, “we observe that the baby’s addiction is transferred on to food. One of the more significant findings in saliva of babies relates to the studies of gut/brain access. Saliva is integral to our stomach, telling our brain when it’s time to eat and when it’s time to stop. Premature babies don’t know when to eat and how to eat. They’re functioning as if they’re still in the womb.”

Neo natal saliva research is opening doors and windows to a vast landscape of cures and treatments.

*

If you care about immunity protection for the organ of the eyes, listen to these programs.

They feature wisdom, knowledge, new technology and health tips for better living every week on the internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist®, naturally pH balanced water technology for acid mantle protection on VoiceAmerica World Talk Radio & Apple iTunes with Program Director Rose Hong of Global Dragon TV with Sharon Kleyne.

LISTEN to the internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist®, FDA approved, naturally pH balanced water technology for acid mantle protection, on VoiceAmerica World Talk Radio & Apple iTunes. This program features Dr. Jill Maron, Professor of Pediatrics and Vice Chair of Pediatric Research at Tufts Children’s Hospital, Boston, MA.

Follow this link: https://www.voiceamerica.com/episode/126816/encore-the-power-of-neonatal-saliva

Some recent Sharon Kleyne talk radio programs feature:

Dr. David T.W. Wong, DMD, DMSC https://www.voiceamerica.com/episode/125933/saliva-diagnostics

Nancy Yonally Coleman & James Derick https://www.voiceamerica.com/episode/125837/be-safe-strategies-for-you-and-your-families-to-go-back-to-school-and-work-safely-during-covid

Dr. David Clarke https://www.voiceamerica.com/episode/125671/hidden-stresses-and-your-health

If you would like to watch a brief, entertaining educational film that demonstrates the application of the new Dry Eye Solution® technology Nature’s Tears® EyeMist®, sponsor of Sharon Kleyne’s talk radio program, go here: https://www.youtube.com/watch?v=l0gOr8TB45U

Share article on social media or email:

Healthcare Executive Joseph Smith Joins the DataOceans Advisory Board


Healthcare executive Joseph Smith joins the DataOceans advisory board

“The health insurance industry is in need of new solutions to leverage growing volumes of EHR data to improve efficiencies and patient outcomes. I’m very pleased to join DataOceans’ advisory board to help them continue to deliver the next generation of communications to their clients.”

DataOceans LLC, (https://www.dataoceans.com) a leading customer communications management (CCM) platform, today announced that Joseph Smith has joined its Advisory Board.

Mr. Smith had held leadership positions in the healthcare insurance industry, including Blue Cross Blue Shield (BCBS) organizations in the Midwest, Northeast and Southwest. He recently retired from his role as Senior Vice President and CIO at Arkansas Blue Cross and Blue Shield.

Speaking of the new affiliation, DataOceans’ founder and CEO Larry Buckley commented, “Joe brings to us decades of leadership in healthcare IT governance and strategy. His deep understanding of these areas will be a valuable contribution that will help us continue to deliver innovative customer communications for our clients in the healthcare industry.”

Throughout his career Mr. Smith has served in numerous healthcare leadership roles, on several occasions representing BCBS in formal testimony to Committees of Congress. In 2011 he was selected to receive Information & Technology Magazine’s “Elite 8” Award. He has also been awarded a patent for the business strategy and supporting computer system to support the healthcare industry’s migration to ICD 10 coding nomenclature.

Mr. Smith has founded four major user groups for shared systems investments, and currently serves as an advisor to firms and committees in the technology and healthcare sectors. He is the founder of several healthcare-related companies: Shareware LLC, a shared capabilities company; Shared Health Plan Systems LLC, which enables multiple health plans to administer their health products on a single shared operations platform; and HITvision, which specializes in Healthcare IT arbitration.

According to Smith, “The health insurance industry is in need of new solutions to leverage growing volumes of EHR data to improve efficiencies and patient outcomes. I’m very pleased to join DataOceans’ advisory board to help them continue to deliver the next generation of communications to their clients.”

About DataOceans. DataOceans delivers a fully integrated and comprehensive CCM platform built for communications and revenue lifecycle management, where business rules can be applied to deliver agile and consistent communications, including billing statements, compliance notifications, and marketing promotions, across distribution channels that include print, online, mobile, interactive PDF and mobile alerts. DataOceans enables clients to transform how they engage with customers, innovate how they do business, and simplify their technology landscape. For more information, visit https://www.dataoceans.com or follow us on LinkedIn at https://www.linkedin.com/company/dataoceans/

Share article on social media or email:

The Top 25 Healthcare Technology CEOs of Asia for 2020


The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology CEOs of Asia for 2020. The healthcare technology industry is facing more pressure than ever before as the demand for new treatments, devices, and digital solutions reaches new heights. Strong and inventive leadership is needed in order for companies to keep up with this evolving market, and the CEOs represented on this year’s list exemplify both of those qualities and more. They have successfully guided their companies to become leaders in their fields, in both Asia and the global healthcare technology sector while fostering growth and innovation within their workforces.

Among this year’s notable achievements, Dharmil Sheth has seen his company PharmEasy double its business each year to become one of the largest pharmaceutical technology platforms in the industry. Similarly, DXY has seen four successful funding rounds under the guidance of CEO Jin Zhang, totaling $182 million in funding raised to date. These accomplishments demonstrate the expert strategy employed by these leaders in developing products and services that are not only financially promising, but also widely beneficial to the health of populations around the world.

Through their dedication to improving global health, their ability to build and guide their organizations, and their specific domains of expertise, these individuals have made their mark. The Healthcare Technology Report team celebrates the achievements of this year’s Top 25 Healthcare Technology CEOs of Asia for 2020.

Congratulations to each of this year’s awardees.

David Chang (WuXi AppTec), Peter DeYoung (Piramal Group), John Oyler (BeiGene), Sanjiv Navangul (Bharat Serums and Vaccines), Shashank ND (Practo), Alex Li (United Imaging Healthcare), Dharmil Sheth (PharmEasy), Jonathan Sudharta (Halodoc), Tushar Vashisht (HealthifyMe), Vedam Ramprasad (MedGenome), Deepak Sahni (Healthians), Prashant Jhaveri (MediBuddy), Jin Zhang (DXY), Toru Nishikawa (Preferred Networks), Michelle Xia (Akeso Biopharma), Mukesh Parmar (Docplexus), Avi Lasarow (Prenetics), Silviu Itescu (Mesoblast), Minhong Jang (Lunit), Jingsong Wang (Harbour BioMed), Colin Denver (SpeeDx), Shailesh Prithani (Doxper), Li Chen (Hua Medicine), Daniel Carraway (RWDC Industries), and Sudhir Srivastava (SS Innovations).

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.

Share article on social media or email:

Glint Pharmaceuticals Announces Formation of Clinical Advisory Board


Glint Pharmaceuticals announces the formation of a clinical advisory board composed of notable and experienced clinicians in ophthalmology and optometry.

The clinicians on the advisory board include: Dr. Mark Abelson, Founder ORA, Inc., Dr. Cynthia Matossian, Medical Director, Matossian Eye Associates, an affiliate of Prism Vision Group, Dr. James Thimons, Medical Director, Ophthalmic Consultants of Connecticut, Dr. Mark Blecher, Professor Ophthalmology, Wills Eye Hospital and Dr. Paul Karpecki, Director, Kentucky Eye Institute,

“We are grateful to have such an experienced and knowledgeable group of clinicians join our advisory board to guide the development of our drug delivery technology to treat significant medical eye disease,” says Chris Adams CEO.

About Glint

Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance.

Share article on social media or email:

New Study By Kids Neuro Clinic and Rehab Center At Dubai Healthcare City Shares Treatment Success in Autism Spectrum Disorder – Is There Light at The End of The Tunnel?


Kids Neuro Clinic and Rehab Center, Dubai announces today groundbreaking findings of a new research study on the treatment of Autism Spectrum Disorder (ASD) in younger children. The results, published in the international, peer-reviewed journal, Neuropsychiatric Disease and Treatment, share breakthrough findings in ASD research. For the first time in medical literature, researchers describe a complete resolution of ASD core signs and symptoms using a combination of FDA approved pharmacological medications and standard supportive therapies.

Autism spectrum disorder (ASD) is a lifelong debilitating neurodevelopmental disorder characterized by repetitive and restricted patterns of behavior, difficulties with communication and social interaction.

Worldwide, the prevalence of ASD is increasing at an alarming rate yet understanding causes of ASD still at large remain unclear. It is well documented however, that care and management for ASD patients has a significant socioeconomic impact consistently across the globe.

Due to limitations of published data on costs of ASD patient management locally, a review of published data in the United States of America, where ASD affects one in 59 children, showed societal costs of managing ASD in 2015 were a staggering $268 billion. This figure, which had increased more than six-fold since 2006, is further estimated to rise to $461 billion by 2025 following existing treatment approaches. This data highlights the critical need for progressing knowledge to support ASD treatment and management.

Currently, ASD is considered to be a non-curable disorder. As stated in the National Institute of Neurological Disorders and Stroke (NINDS, USA) fact sheet for ASD, “There is no cure for ASD. Therapies and behavioral interventions are designed to remedy specific symptoms and can improve those symptoms.” [1]

However, recent findings published by Dr. Hamza Alsayouf at the Kids Neuro Clinic and Rehab Center in Dubai, provide promising hope. This pivotal study shares data which reveals pharmacological intervention resulted in an absolute and complete resolution of ASD core signs and symptoms in younger children aged four and older. [2]

In this study, 18 children diagnosed with ASD were successfully treated following treatment protocols developed by the Dubai Healthcare City based center, using risperidone and aripiprazole. Both drugs, which are US Food and Drug Administration (FDA) approved, are used for the treatment of challenging behaviors such as irritability, aggression, and self-injury that coexist with ASD in children aged five and above. The findings reported in this study include ten patients (56%) showing unprecedented complete resolution of their core ASD signs and symptoms, while the remaining eight patients (44%) exhibiting significant improvements in their symptoms ranging from 60 to 80%. Furthermore, these improvements were reported stable with no regression observed during the follow-up period.

These breakthrough findings are the result of Dr Hamza Alsayouf’s, Director of Kids Neuro Clinic and Rehab Center. dedicated and long-term commitment to advance knowledge on the use of pharmacological intervention in ASD. “We are extremely pleased that our research is being published at an international platform. This is an area of much-needed focus. This study shows for the first time that, against the prevailing opinion, ASD signs and symptoms can indeed be completely resolved,” said Dr. Alsayouf. He further added, “While we have many video testimonials for ASD children who have been treated successfully at our center over the years, our aim was to ensure our impressive results are published in reputable scientific literature to substantiate our experience in the treatment of ASD.”

This retrospective study expands the evidence-based use of FDA-approved medications that have been available for many years and believed only be effective in managing behavioral issues. “Based on our extensive center experience and applying in-depth scientific evidence, we have demonstrated that use of these medications can help to target the core signs and symptoms of ASD, and not just to treat behavioral issues. We strongly believe that ASD is neuropsychiatric in nature and shares many features with other neuropsychiatric diseases and needs to be approached the same way,” said Dr. Alsayouf.

“We have found chronic use of these medications for more than one to two years is key as well as individualizing treatment plans. Finding the optimal combination and tailoring doses of medications for each patient following a personalized approach is crucial and it is imperative to optimize overall patient outcome. As this study shows, when indicated, the use of ADHD medications in addition to antipsychotic medications helped control ADHD symptoms and boost attention which plays a major role in the learning process,” added Dr. Alsayouf.

In the study, Dr. Alsayouf provided a treatment algorithm and explained every patient’s treatment journey, with the hope to stimulate further controlled clinical research.

This study shows that early tailored pharmacological intervention along with early intervention standard supportive therapies can successfully treat core signs and symptoms in younger ASD patients. It is anticipated that a double-blinded, placebo-controlled study will be performed to validate these findings and further support development of a cure for this chronic and devastating disorder.

As Dr. Alsayouf concluded, “While it may take us decades to uncover the underlying causes of ASD, this should not divert our attention away from treating this debilitating condition from what we know today. We believe our case series will prove to be a big eye-opener.”

The study appears in volume 20 of Neuropsychiatric Disease and Treatment.

About Dr. Hamza A Alsayouf, MD

Dr. Alsayouf is an American Board-certified Pediatric Neurologist who completed his training at Nationwide Children’s Hospital, Ohio State University, from 2006–2009. He is the founder and owner of the Kids Neuro Clinic and Rehab Center at Dubai Healthcare City, Dubai, UAE.

About the Journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed and open-access journal, (5-year impact factor, 2.6) reporting on clinical therapeutics and pharmacology research on a range of neuropsychiatric and neurological disorders. Neuropsychiatric Disease and Treatment is the official journal of The International Neuropsychiatric Association (INA).

About the Study Center

Kids Neuro Clinic and Rehab Center is a pediatric neurology clinic and pediatric rehabilitation center located in Dubai Healthcare City. The Center is the first independent pediatric neuroscience facility in Dubai that specializes in child neurology and child rehabilitation.

Kids Neuro Clinic and Rehab Center intends to publish further research in this area and encourages interest from individuals and industry wishing to collaborate in its ASD research program.

Website: https://www.kidsneuroandrehab.com/

For more information, please contact:

Dr. Hamza Alsayouf

Email: Leeamra1000@gmail.com

Tel: 0097145570326

References

NIH National Institute of Neurological Disorders and Stroke. Autism Spectrum Disorder Fact Sheet. September 2015. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Autism-Spectrum-Disorder-Fact-Sheet

Alsayouf HA, Talo H, Biddappa ML, et al. Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series. Neuropsychiatric Disease and Treatment. https://www.dovepress.com/pharmacological-intervention-in-children-with-autism-spectrum-disorder-peer-reviewed-fulltext-article-NDT

Texas Monthly Super Doctors 2020 recognizes 35 U.S. Dermatology Partners physicians in peer-nominated award


U.S. Dermatology Partners Physicians recognized in peer-nominated Texas Monthly Super Doctor award

U.S. Dermatology Partners Physicians recognized in peer-nominated Texas Monthly Super Doctor award

“We are proud to have so many of our physicians honored by their peers for their achievements. Their inclusion in this prestigious award is a tribute to their dedication to our organization’s purpose of delivering ethical and exceptional patient care experiences,” said Paul Singh, CEO

U.S. Dermatology Partners is proud to announce 35 U.S. Dermatology Partners doctors are being recognized by their peers in Texas Monthly Magazine. Of those, 24 are being recognized as Super Doctors® in the December 2020 issue of Texas Monthly. Nine will be recognized as members of the Super Doctors Hall of Fame and five of the nine have been voted by peers since the inception of the award. Hall of Fame members are those who have been selected for 10 or more years. As one of the medical field’s most prestigious titles, only 5% of the state’s physicians receive this designation.

An additional eleven U.S. Dermatology Partners doctors were recognized as Rising Stars in the July 2020 issue of Texas Monthly. Doctors recognized as Rising Stars meet the same criteria as Super Doctors and have been actively practicing for 10 years or less. Only 2.5% of all active physicians are selected to the Rising Star list.

Each year, Texas Monthly asks doctors across the state to nominate colleagues (excluding themselves) who they would trust for their own medical care. The Super Doctors research team then investigates independently. Candidates are evaluated based on peer recognition, professional achievement, and disciplinary history. Candidates are also rated on their involvement in scientific publications, medical research, participation in lectures, and other professional activities. The highest-ranking nominated physicians are asked to serve on a selection panel of peers, which helps to determine the final list of Super Doctors.

U.S. Dermatology Partners began in 2013 and has grown to one of the largest single-specialty dermatology practices in the country. The group is focused on attracting and retaining the top physicians in the field of dermatology and also includes fellowship-trained Mohs Surgeons and dermatopathologists. The Texas Super Doctors is a unique award, designed to benefit educated consumers seeking exceptional care. Physicians from U.S. Dermatology Partners have been named as recipients of this prestigious award for six consecutive years with a growing number of U.S Dermatology Partners physicians receiving the award each year. U.S. Dermatology Partners can be found in over 50 locations throughout the state of Texas. To find a dermatologist near you go to http://www.usdermatologypartners.com.

“We are proud to have so many of our physicians honored by their peers for their professional excellence and achievements. Their inclusion in this prestigious award is a tribute to their dedication to our organization’s purpose of delivering ethical and exceptional patient care experiences,” said Paul Singh, CEO

The physicians being honored represent cities throughout the state of Texas including Dallas, Fort Worth, Plano, Sherman, Grapevine, Austin, Georgetown, Cedar Park, Carrollton, Houston, San Antonio, and Tyler.

The complete list is published in the December 2020 issue of Texas Monthly.

U.S. Dermatology Partners Super Doctors Legacy Hall of Fame 2020

Recognized for Dermatology

Lawrence L. Anderson, M.D., Tyler – 16 years

Aaron Joseph, M.D., Pasadena – 15 years

Howard A. Rubin, M.D., Dallas – 16 years

Hans M. Sander, M.D., Austin – 16 years

Dale G. Schaefer, M.D., Austin – 17 years

U.S. Dermatology Partners Super Doctors Hall of Fame 2020

Recognized for Dermatology

Elizabeth Basler, M.D., Houston

Mark Koone, M.D., Sherman

Mark A. Price, M.D., Houston

Danny R. Thomas, M.D., Fort Worth

U.S. Dermatology Partners Super Doctors 2019

Recognized for Dermatology

Alma Criseida Berlingeri-Ramos, M.D., Tyler

Roopal Bhatt, M.D., Austin

Jessica Dorsey, M.D., Cedar Park

Cindy Greenberg, M.D., Houston

Aubrey Chad Hartmann, M.D., Cedar Park

Jordan Ilse, M.D., Belton

John LeVasseur, MD San Antonio

Monica Madray, M.D., Georgetown

Amy A. McClung, M.D., Austin

Shanna Burris Meads, M.D., Tyler

Clint Moss, M.D., Sherman

Bryan Selkin, M.D., Plano

Howard Steinman, M.D. Carrollton, Plano, Grapevine

Breck Thrash, M.D., Dallas

Bryan L. Townsend, M.D., Austin

U.S. Dermatology Partners Rising Stars 2020

Recognized for Dermatology

Caitlin Farmer, M.D., Flower Mound, Plano

Jennifer Holman, M.D., Tyler

Weilan Johnson, M.D., Georgetown

Laura Lester, M.D., Cedar Park

Bobbak Mansouri, M.D., Tyler

Michaela Overturf, M.D., Nacogdoches

Trisha Patel, M.D., Dallas

Valerie Truong, M.D., Dallas, Plano

Daniel Walker, MD, Grapevine

Calvin Williams, M.D., Keller

John “Jay” Wofford, MD, Dallas, Plano

About U.S. Dermatology Partners

As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners patients not only have access to general medical, surgical, and cosmetic skin treatment through its coordinated care network, but also benefit from the practice’s strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit usdermatologypartners.com.

New COVID-19 Management Features for EntroWatch Access Control


These new features are part of the ongoing development of the EntroWatch platform and can help building owners and managers to ensure safe social distancing and protection from the potential risk of a Coronavirus infection

The latest version of EntroWatch includes several new features to help make buildings COVID-19 Secure. EntroWatch is the award-winning access control software for Entro series door controllers and contactless card readers and keypads. The new COVID-19 management features include occupancy management, temperature & mask screening and contact tracing.

Occupancy management can be used to manage social distancing and prevent overcrowding in an EntroWatch controlled building. Occupancy levels can be set for rooms whose doors have access control readers. Examples include offices, meeting rooms, laboratories, tool rooms, canteens & rest areas. EntroWatch displays occupancy levels, supports ‘one in and one out’ access and can be set to alarm if someone tries to exceed the occupancy threshold level.

The temperature & mask screening feature makes use of compatible camera technologies placed strategically within a building. As people pass one of these cameras, they are screened for temperature and whether they are wearing a mask or not. Based on threshold levels and settings, a person is either allowed to enter or exit an EntroWatch access controlled door or not. A snapshot of their temperature is stored in EntroWatch.

Contact tracing is an enhanced report within EntroWatch 3.1 based on the access control principle of Who, Where and When. The report can be used to track and trace people within a building.

“We have responded rapidly to requests from our clients to extend EntroWatch features for pandemic management” commented David Ross, Remsdaq’s UK Security Business Development Manager. “These new features are part of the ongoing development of the EntroWatch platform and can help building owners and managers to ensure safe social distancing and protection from the potential risk of a Coronavirus infection.”

The Entro series utilises the native BACnet/IP protocol; the open communications standard for the building automation industry. Using BACnet provides the opportunity to integrate the Entro series into an intelligent building management system, for population and movement data for analytics and rule-based energy usage. The Entro series includes the EntroStar (two-door) and EntroNet (eight-door) access door controllers, EntroPad card readers, keypad and management kit and EntroPass secure credential. For UK government sites Remsdaq supplies a Certified Secure CPNI version of the Entro system.

More information:

Robin Koffler – Sales & Marketing Director

Mobile: 07788 720 979 | Email: rk@remsdaq.com | Social: @remsdaq

Website: https://www.remsdaq.com/entro-series

Photo Image Available – The Entro access control system

About Remsdaq Ltd

Remsdaq Ltd is a privately held company started in 1974, specialising in SCADA, integrated security and mobilisation systems. Routes to market include utilities and industrial end-users (SCADA), Blue Light Emergency Services (mobilisation software) and IT/Security distribution channels (access security products) via strategic regional partners, distributors and value-added resellers. The company operates from a 4,000m² facility on the Deeside Industrial Park (on the Cheshire/North Wales border) and provides a turnkey service including complete lifecycle support from concept to design, project management, installation, commissioning and maintenance.

Share article on social media or email:

Help.org Names the Best Drug and Alcohol Rehab Centers in Springfield


News Image

Help.org, a trusted online resource for individuals who struggle with addiction and their loved ones, has announced the Best Rehab Facilities in Springfield, MO for 2021. The informational guide recognizes the top 7 rehab facilities based on cost, treatment options, location, accompanying services, and more.

According to recent studies, drug overdose is the leading cause of death among people under age 50. In Springfield, deaths related to opioid abuse increased significantly from 2011 to 2015. Substance abuse among adolescents is also escalating in Springfield with 55 percent of high school students reported using alcohol, 38 percent reported using marijuana, 8 percent reported using prescription drugs without a valid prescription, and 2 percent reported using heroin. With the growing need for accessible and high-quality rehab programs, Help.org has developed a unique ranking process to help connect individuals with treatment providers that meet their needs.

The Help.org research team analyzed thousands of facilities across the country and then identified the most cost-effective and highest-rated programs in larger cities like Springfield. Each facility was evaluated based on rehabilitation services, treatment approaches, cost, special programs for unique demographics, and ancillary services. The website also provides information about drug use and side effects as well as educational articles. For a detailed listing of the Best Rehab Facilities in Springfield, MO please visit https://www.help.org/drug-and-alcohol-rehab-centers-in-springfield-mo

2020 Best Rehab Facilities in Springfield, MO (in alphabetical order)

A&M Recovery

3322 South Campbell, Suite P&Q

Springfield, MO 65807

417-823-3808

BHG Springfield Treatment Center

404 East Battlefield Road

Springfield, MO 65807

417-865-8045

Burrell Behavioral Health

1350 East Bradford Parkway

Springfield, MO 65804

417-761-5000

CoxHealth

1423 North Jefferson Avenue

Springfield, MO 65802

417-269-2273

Higher Ground Recovery Center

2032 East Kearney Street, Suite 214

Springfield, MO 65803

417-869-0700

Preferred Family Healthcare

2626 West College Road

Springfield, MO 65802

660-665-1962

Synergy Counselling Center

1717 East Republic Road

Springfield, MO 65804

417-351-4282

ABOUT HELP.ORG

Help.org is an online resource for individuals who struggle with addiction and their loved ones. The website provides the latest research through scientifically proven methods, community recovery resources as well as information about local financial assistance. Help.org’s team of researchers, activists, and writers work together with addiction counselors and other professionals to offer useful and accurate resources to help individuals seeking recovery. To learn more, visit https://www.help.org/.

Share article on social media or email:

Help.org Names the Best Drug and Alcohol Rehab Centers in Malibu


News Image

Help.org, a trusted online resource for individuals who struggle with addiction and their loved ones, has announced the Best Rehab Facilities in Malibu, CA for 2021. The informational guide recognizes the top 15 rehab facilities based on cost, treatment options, location, accompanying services, and more.

According to recent studies, drug overdose is the leading cause of death among people under age 50. In Malibu, deaths related to opioid abuse increased significantly from 2011 to 2015. Substance abuse among adolescents is also escalating in Malibu with 55 percent of high school students reported using alcohol, 38 percent reported using marijuana, 8 percent reported using prescription drugs without a valid prescription, and 2 percent reported using heroin. With the growing need for accessible and high-quality rehab programs, Help.org has developed a unique ranking process to help connect individuals with treatment providers that meet their needs.

The Help.org research team analyzed thousands of facilities across the country and then identified the most cost-effective and highest-rated programs in larger cities like Malibu. Each facility was evaluated based on rehabilitation services, treatment approaches, cost, special programs for unique demographics, and ancillary services. The website also provides information about drug use and side effects as well as educational articles. For a detailed listing of the Best Rehab Facilities in Malibu, CA please visit https://www.help.org/drug-and-alcohol-rehab-centers-in-malibu-ca

2020 Best Rehab Facilities in Malibu, CA (in alphabetical order)

Alo House Recovery Center

28955 Pacific Coast Highway #200

Malibu, CA 90265

888-409-1774

Avalon Malibu

32420 Pacific Coast Highway

Malibu, CA 90265

888-732-0463

Beach House Treatment Centers

22601 Pacific Coast Highway, Suite 250

Malibu, CA 90265

310-448-1413

Broad Beach Recovery Center

31217 Bailard Road

Malibu, CA 90265

310-263-8699

Cliffside Malibu

29160 Heathercliff Road #100

Malibu, CA 90265

855-335-0850

Inspire Malibu

30101 Agoura Court, Suite 103

Agoura Hills, CA 91301

800-444-1838

Journey Malibu

22516 Carbon Mesa Road

Malibu, CA 90265

877-673-4225

LifeSync Malibu

28632 Roadside Drive, Suite 235

Agoura Hills, CA 91301

866-491-4426

Malibu Hills Treatment Center

415 Westlake Boulevard

Malibu, CA 90265

888-415-3483

Milestones Ranch

327 Latigo Canyon Road

Malibu, CA 90265

866-874-9774

Oceanside Malibu Addiction Treatment Center

21022 Pacific Coast Highway

Malibu, CA 90265

866-738-6550

Passages Addiction Treatment Centers

6428 Meadows Court

Malibu, CA 90265

888-920-8849

Riviera Recovery

2827 South Barrington Avenue

Los Angeles, CA 90064

855-207-9708

Seasons In Malibu

31739 Pacific Coast Highway

Malibu, CA 90265

866-780-8539

Summit Malibu

27026 Sea Vista Drive

Malibu, CA 90265

310-742-1882

ABOUT HELP.ORG

Help.org is an online resource for individuals who struggle with addiction and their loved ones. The website provides the latest research through scientifically proven methods, community recovery resources as well as information about local financial assistance. Help.org’s team of researchers, activists, and writers work together with addiction counselors and other professionals to offer useful and accurate resources to help individuals seeking recovery. To learn more, visit https://www.help.org/.

Share article on social media or email:

Help.org Names the Best Drug and Alcohol Rehab Centers in Rochester


News Image

Help.org, a trusted online resource for individuals who struggle with addiction and their loved ones, has announced the Best Rehab Facilities in Rochester, NY for 2021. The informational guide recognizes the top 6 rehab facilities based on cost, treatment options, location, accompanying services, and more.

According to recent studies, drug overdose is the leading cause of death among people under age 50. In Rochester, deaths related to opioid abuse increased significantly from 2011 to 2015. Substance abuse among adolescents is also escalating in Rochester with 55 percent of high school students reported using alcohol, 38 percent reported using marijuana, 8 percent reported using prescription drugs without a valid prescription, and 2 percent reported using heroin. With the growing need for accessible and high-quality rehab programs, Help.org has developed a unique ranking process to help connect individuals with treatment providers that meet their needs.

The Help.org research team analyzed thousands of facilities across the country and then identified the most cost-effective and highest-rated programs in larger cities like Rochester. Each facility was evaluated based on rehabilitation services, treatment approaches, cost, special programs for unique demographics, and ancillary services. The website also provides information about drug use and side effects as well as educational articles. For a detailed listing of the Best Rehab Facilities in Rochester, NY please visit https://www.help.org/drug-and-alcohol-rehab-centers-in-rochester-ny

2020 Best Rehab Facilities in Rochester, NY (in alphabetical order)

Delphi Rise

835 West Main Street

Rochester, NY 14611

585-467-2230

Huther Doyle Memorial Institute

360 East Avenue

Rochester, NY 14604

585-325-5100

Rochester Evaluation Center

1350 University Avenue

Rochester, NY 14607

585-287-5622

Rochester Regional Health

1565 Long Pond Road

Rochester, NY 14624

585-922-9900

UR Medicine-Outpatient Chemical Dependency Services

2613 West Henrietta Road, Suites C & D

Rochester, NY 14623

585-275-5400

Westfall Associates Inc. Outpatient

919 Westfall Road

Rochester, NY 14618

585-473-1500

ABOUT HELP.ORG

Help.org is an online resource for individuals who struggle with addiction and their loved ones. The website provides the latest research through scientifically proven methods, community recovery resources as well as information about local financial assistance. Help.org’s team of researchers, activists, and writers work together with addiction counselors and other professionals to offer useful and accurate resources to help individuals seeking recovery. To learn more, visit https://www.help.org/.

Share article on social media or email: